Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 14/20 | 0.50 |
| ▸ | CA2 | P00918 | 13/20 | 0.50 |
| ▸ | CA12 | O43570 | 8/20 | 0.50 |
| ▸ | CA1 | P00915 | 8/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524295 | 1.00 | CA9 (0.50) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL23523937 | 0.90 | CA9 (0.45) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL30355643 | 0.90 | CA9 (0.45) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL30355448 | 0.89 | HDAC4 (0.43) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL23524153 | 0.89 | HDAC4 (0.43) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL30355393 | 0.89 | CA2 (0.37) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL23524366 | 0.89 | CA2 (0.37) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL23523721 | 0.88 | NPC1 (0.38) | S1PR1 | |
| SCHEMBL23523716 | 0.87 | NPC1 (0.43) | — | |
| SCHEMBL30355571 | 0.87 | NPC1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | CA9 4628/4885CA2 3359/4885CA12 4698/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | CA9 3668/4885CA2 825/4885CA12 2815/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | CA9 4628/4885CA2 3359/4885CA12 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.